SCHEMBL3883548

SCHEMBL3883548

O=C(O)CCc1ccc(OC2CCCC2)c(-c2cccc3[nH]ccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.46
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
S1PR1 P21453 1/20 0.40
GYS1 P13807 1/20 0.38
PDE4B Q07343 2/20 0.38
HTR1A P08908 7/20 0.38
BRD4 O60885 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
PDE4A P27815 2/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881792 0.99 FFAR4 (0.45) FFAR4THRATHRBS1PR1GYS1
SCHEMBL3883912 0.89 HDAC1 (0.41) PDE4BHTR1ABRD4HDAC1HDAC2
SCHEMBL3887988 0.88 HDAC1 (0.41) PDE4BHTR1ABRD4HDAC1HDAC2
SCHEMBL3686227 0.87 THRA (0.43) FFAR4THRATHRBS1PR1GYS1
SCHEMBL3881280 0.86 THRA (0.45) FFAR4THRATHRBS1PR1GYS1
SCHEMBL3687145 0.84 FFAR4 (0.44) FFAR4THRATHRBS1PR1BRD4
SCHEMBL3883911 0.83 KDM4E (0.40) GYS1PDE4BHTR1ABRD4PDE4A
SCHEMBL3896075 0.82 KDM4E (0.39) PDE4BHTR1ABRD4PDE4APDE4C
SCHEMBL3678537 0.80 FFAR4 (0.50) FFAR4THRATHRBS1PR1PDE4B
SCHEMBL3884350 0.79 FFAR4 (0.41) FFAR4THRATHRBS1PR1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN claimed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN disclosed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885THRA 1720/4885THRB 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.